Reply to: The best predictive model for post-SVR HCC: can it be universal?

Hepatol Int. 2022 Jun;16(3):729. doi: 10.1007/s12072-022-10349-0. Epub 2022 May 12.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antiviral Agents / therapeutic use
  • Carcinoma, Hepatocellular*
  • Humans
  • Liver Cirrhosis / drug therapy
  • Liver Neoplasms*
  • Sustained Virologic Response

Substances

  • Antiviral Agents